Trial Profile

Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Apr 2025 According to a PharmaMar media release, the rapid oral abstract presentation of this study at the 2025 ASCO will be done by Santiago Ponce, MD, PhD on 1 June 2025 (04:30 PM- 06:00 PM CDT), at the session named- " Lung Cancer- Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers".
23 Apr 2025 According to Jazz Pharmaceuticals plc media release, a rapid oral abstract of this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 30-June 3, 2025, in Chicago and online.
15 Nov 2023 Planned number of patients changed from 25 to 184.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com